

ASX Release

Anatara Lifesciences announces the appointment of new Non-Executive Chairman and Non-Executive Director & corporate advisor

Key points:

- **Sue MacLeman has been appointed Non-Executive Chairman. Sue has over 25 years experience as a pharmaceutical, biotechnology and medical technology executive having held senior roles at Schering-Plough Corporation (now Merck), Amgen, Bristol-Myers Squibb and Mesoblast.**
- **Dr Jane Ryan has been appointed Non-Executive Director. Jane has over 25 years of international experience in the pharmaceutical and biotechnology industries where she has managed research and development programs for companies such as Peptech, Roche, Cambridge Antibody Technology and Biota Holdings.**
- **Peloton Capital Pty Ltd (AFSL 406040) has been appointed as corporate advisor to assist Anatara with its capital markets and investor relations strategy.**

BRISBANE & MELBOURNE, 29th August 2018: Anatara Lifesciences (ASX:ANR) is pleased to announce the appointment of two human health focused directors to the Anatara Lifesciences Board of Directors, with Sue MacLeman joining as Non-Executive Chairman and Dr. Jane Ryan as Non-Executive Director from September 1, 2018.

Sue MacLeman will take over the role of Non-Executive Chairman from Dr. Jay Hetzel, who as Interim Chairman has led the Company since the retirement of Dr Mel Bridges, Co-Founder, Chairman & CEO earlier in the year.

Following the commercial decision to focus on the development of products and technologies in the human health sector focused on gut health, the Board has undertaken an extensive search to identify new directors with the relevant background and experience which has resulted in these appointments.

“I am delighted to be joining Anatara at such an exciting time. Anatara is now focused on developing its human product pipeline for gastrointestinal health applications and this is a significant market opportunity which will be of interest to investors and patients,” said Sue MacLeman.

Sue MacLeman

Sue has more than 25 years' experience as a pharmaceutical, biotechnology and medical technology executive with senior roles at Schering-Plough Corporation (now Merck) Amgen, Bristol-Myers Squibb and Mesoblast. Sue recently stepped down from her role as Managing Director and Chief Executive Officer of the Medical Technologies and Pharmaceuticals Growth Centre (MTPConnect) where she will take up the role of non-executive chairman later in the year.

Sue brings a unique set of experiences in technology commercialisation, strategic planning, capital markets and fund raising, M&A and alliance management.

Dr Jane Ryan

Jane has over 25 years of international experience in the pharmaceutical and biotechnology industries where she has managed research and development programs and held key roles in business development and alliance management. Jane has worked both in Australia and internationally with companies including Peptech, Roche, Cambridge Antibody Technology and Biota Holdings. Throughout her career, Jane has led many successful fundraising campaigns including the awarding of a \$230m US Government contract. Jane currently chairs the Advisory Board at the ithree Institute at the University of Technology Sydney (UTS) which studies how microbes grow, live, adapt and survive.

As a result of these appointments, Paul Grujic will stand down on August 31 from the Anantara Board and also Dr Jay Hetzel has indicated he will retire as a Director at the AGM in November 2018 following a successful handover to the new Chair. Iain Ross, non-executive director and Dr. Tracie Ramsdale, who is currently Acting CEO will remain on the Anantara Board. An extensive search to identify a new CEO, with relevant experience is underway.

Dr Jay Hetzel commented, "We have been very fortunate to attract two such high caliber individuals to join our Board and I am delighted to be handing over the baton to Sue MacLeman who is well equipped to lead the Board through the next stage of the Company's development.

I want to thank Paul Grujic for his contribution as a Board member since 2014 and particularly for his wise counsel during my time as Interim Chairman.

I am confident that the newly evolved board backed by a talented management team has the experience and tenacity to build this Company going forward and to create lasting shareholder value".

Appointment of Corporate Advisor

Anantara Lifesciences is pleased to announce it has appointed Peloton Capital (AFSL 406040) as corporate advisor to assist the Company with its capital markets and investor relations strategy as the Company re-orientates its strategy to focusing on human health, specifically IBS and IBD. Anantara remains fully funded to execute on its human health strategy. In line with the Company's aim of maximizing shareholder value, the Company

has issued Peloton Capital 750,000 options at an exercise price of \$1.45. The options expire on the 14th of December 2020.

About Peloton Capital

Peloton Capital Pty Ltd ACN 149 540 018 AFSL 406040 (Peloton Capital) was founded in 2011 and specialises in providing investment, corporate advisory, investor relations, mergers and acquisitions, securities trading and wealth management solutions.

For more information please contact:

Investor inquiries	Media inquiries
Dr Jay Hetzel Anatara Lifesciences +61 (0) 413 045 478 jhetzel@anatara.com	Jane Lowe IR Department +61 (0) 411 117 774 jane.lowe@irdepartment.com.au

About Anatara Lifesciences

Anatara Lifesciences (ASX: ANR) develops and aims to partner non-antibiotic, oral products for gastrointestinal diseases in animals and humans where there is significant unmet need and large market opportunity. In May 2018, Anatara granted an exclusive licence to the leading global animal health company, Zoetis Inc., for the worldwide development, manufacturing, distribution and marketing of its lead product Detach as a non-antibiotic approach to aid in the control of diarrhoeal disease (known as scour) in livestock and in horses. Anatara is now focused on developing its human product pipeline for gastrointestinal health applications. For more information, please visit www.anataralifesciences.com.